68.16 USD
+0.81 (+1.2%)
68.16 USD
0 (0%)
Overall HALO gets a fundamental rating of 7 out of 10. We evaluated HALO against 530 industry peers in the Biotechnology industry. While HALO belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. HALO has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make HALO suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
In the past year HALO was profitable.
HALO had a positive operating cash flow in the past year.
In the past 5 years HALO has always been profitable.
Each year in the past 5 years HALO had a positive operating cash flow.
1.2 Ratios
The Return On Assets of HALO (26.81%) is better than 97.55% of its industry peers.
HALO has a better Return On Equity (118.17%) than 99.62% of its industry peers.
The Return On Invested Capital of HALO (42.77%) is better than 99.25% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for HALO is in line with the industry average of 18.22%.
The last Return On Invested Capital (42.77%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
Looking at the Profit Margin, with a value of 47.91%, HALO belongs to the top of the industry, outperforming 98.11% of the companies in the same industry.
HALO's Profit Margin has declined in the last couple of years.
HALO's Operating Margin of 59.33% is amongst the best of the industry. HALO outperforms 99.81% of its industry peers.
HALO's Operating Margin has declined in the last couple of years.
HALO has a better Gross Margin (84.55%) than 87.17% of its industry peers.
HALO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
HALO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, HALO has less shares outstanding
HALO has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, HALO has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.04 indicates that HALO is not in any danger for bankruptcy at the moment.
HALO has a Altman-Z score of 5.04. This is in the better half of the industry: HALO outperforms 72.26% of its industry peers.
The Debt to FCF ratio of HALO is 2.51, which is a good value as it means it would take HALO, 2.51 years of fcf income to pay off all of its debts.
HALO has a better Debt to FCF ratio (2.51) than 93.21% of its industry peers.
A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
With a Debt to Equity ratio value of 1.59, HALO is not doing good in the industry: 79.06% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.04 |
ROIC/WACC5.43
WACC7.87%
2.3 Liquidity
A Current Ratio of 1.59 indicates that HALO should not have too much problems paying its short term obligations.
HALO's Current ratio of 1.59 is on the low side compared to the rest of the industry. HALO is outperformed by 81.70% of its industry peers.
HALO has a Quick Ratio of 1.37. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of HALO (1.37) is worse than 83.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.55% over the past year.
Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.12% on average per year.
Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 31.19%.
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
The Earnings Per Share is expected to grow by 17.25% on average over the next years. This is quite good.
Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 12.82% on average per year.
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y31.96%
EPS Next 5Y17.25%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.56%
Revenue Next 5Y12.82%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
HALO is valuated correctly with a Price/Earnings ratio of 12.11.
HALO's Price/Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 96.98% of the companies in the same industry.
When comparing the Price/Earnings ratio of HALO to the average of the S&P500 Index (26.61), we can say HALO is valued rather cheaply.
With a Price/Forward Earnings ratio of 8.22, the valuation of HALO can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 98.87% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.01, HALO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.11 | ||
| Fwd PE | 8.22 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.79% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaply inside the industry as 97.36% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.31 | ||
| EV/EBITDA | 10.43 |
4.3 Compensation for Growth
HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
HALO's earnings are expected to grow with 31.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.24
PEG (5Y)N/A
EPS Next 2Y40.02%
EPS Next 3Y31.96%
5. Dividend
5.1 Amount
No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
68.16
+0.81 (+1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.69%
Inst Owner Change15.59%
Ins Owners0.83%
Ins Owner Change-0.65%
Market Cap8.02B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts77.33
Price Target77.52 (13.73%)
Short Float %10.64%
Short Ratio5.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)0.44%
PT rev (3m)6.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.57%
EPS NY rev (1m)1.91%
EPS NY rev (3m)2.25%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)1.78%
Revenue NY rev (3m)1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.11 | ||
| Fwd PE | 8.22 | ||
| P/S | 6.45 | ||
| P/FCF | 13.31 | ||
| P/OCF | 13.12 | ||
| P/B | 15.91 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.43 |
EPS(TTM)5.63
EY8.26%
EPS(NY)8.29
Fwd EY12.17%
FCF(TTM)5.12
FCFY7.52%
OCF(TTM)5.2
OCFY7.62%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.24
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.04 |
F-Score8
WACC7.87%
ROIC/WACC5.43
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y51.29%
EPS Next 2Y40.02%
EPS Next 3Y31.96%
EPS Next 5Y17.25%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year33.82%
Revenue Next 2Y29.25%
Revenue Next 3Y23.56%
Revenue Next 5Y12.82%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.25%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
What is the valuation status for HALO stock?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 12.11 and the Price/Book (PB) ratio is 15.91.
How financially healthy is HALOZYME THERAPEUTICS INC?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.